Author: admin

“PD-1 and PD-L1 Inhibitors Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the PD-1 and PD-L1 Inhibitors Market.

The PD-1 and PD-L1 Inhibitors Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the PD-1 and PD-L1 Inhibitors Pipeline Report:

• Companies across the globe are diligently working toward developing novel PD-1 and PD-L1 Inhibitors treatment therapies with a considerable amount of success over the years.

• PD-1 and PD-L1 Inhibitors companies working in the treatment market are Compass Therapeutics, Aurigene Discovery Technologies, RemeGen, Aurigene Discovery Technologies, Inhibrx, Effector Therapeutics, CytomX Therapeutics, Innovent Biologics, GlaxoSmithKline, Biocad, Genentech, Bristol Myers Squibb, Merck, and others, are developing therapies for the PD-1 and PD-L1 Inhibitors treatment

• Emerging PD-1 and PD-L1 Inhibitors therapies such as – CTX-8371, CA 327, RC-98, AUR-106, INBRX 105, Tomivosertib, CX-072, IBI 323, Jemperli, BCD-100, TECENTRIQ, Opdivo, KEYTRUDA, and others are expected to have a significant impact on the PD-1 and PD-L1 Inhibitors market in the coming years.

• In May 2025, Clinical-stage biopharma company OmRx Oncology (OmRx) has launched a randomized Phase II trial for its oral PD-L1 inhibitor, OX-4224, aimed at patients with non-small cell lung cancer (NSCLC). The company believes this investigational small molecule could provide a more affordable and accessible alternative to current antibody-based treatments. The open-label study plans to enroll around 50 metastatic NSCLC patients, primarily in India, who have not previously received immune checkpoint inhibitor therapies. OX-4224 will be assessed as a second-line monotherapy in this patient population.

• In March 2025, Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM), a leader in targeted radiotherapies, has announced a new clinical program featuring trials of Actimab-A combined with either KEYTRUDA® (pembrolizumab) or OPDIVO® (nivolumab). These blockbuster PD-1 inhibitors, developed by Merck & Co. and Bristol Myers Squibb respectively, together generated $38.8 billion in sales in 2024 across multiple solid tumor indications. Despite their success, their effectiveness is often limited by Myeloid Derived Suppressor Cells (MDSCs), which accumulate in the tumor microenvironment and express the CD33 antigen — the specific target of Actimab-A. The trials aim to explore whether depleting MDSCs with Actimab-A can enhance the efficacy of these immunotherapies.

• In January 2025, ImmunityBio, Inc. (NASDAQ: IBRX) announced a new collaboration and supply agreement with BeiGene, Ltd. (soon to be renamed BeOne Medicines, Ltd.), a global oncology company, to conduct a pivotal randomized Phase 3 trial (ResQ201A-NSCLC). This trial will combine BeiGene’s PD-1 checkpoint inhibitor, tislelizumab, with ImmunityBio’s ANKTIVA (nogapendekin alfa inbakicept-pmln). The ResQ201A-NSCLC study (NCT06745908) aims to validate the efficacy and safety of this combination, previously shown in the QUILT 3.055 trial, and provide evidence that these two immunotherapies can enhance overall survival in patients with advanced or metastatic NSCLC who have developed resistance to immune CPI treatments.

PD-1 and PD-L1 Inhibitors Overview

PD-1 (programmed cell death protein 1) is found on the surface of cancer cells. It is used by tumors to evade the immune system so blocking its action enables the body to attack and kill cancer. T cells constantly monitor our body for abnormal cells and eliminate them before they can turn into cancer

Get a Free Sample PDF Report to know more about PD-1 and PD-L1 Inhibitors Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/pd-1-and-pd-l1-inhibitors-competitive-landscape

Emerging PD-1 and PD-L1 Inhibitors Drugs Under Different Phases of Clinical Development Include:

• CTX-8371: Compass Therapeutics

• CA 327: Aurigene Discovery Technologies

• RC-98: RemeGen

• AUR-106: Aurigene Discovery Technologies

• INBRX 105: Inhibrx

• Tomivosertib: Effector Therapeutics

• CX-072: CytomX Therapeutics

• IBI 323: Innovent Biologics

• Jemperli: GlaxoSmithKline

• BCD-100: Biocad

• TECENTRIQ: Genentech

• Opdivo: Bristol Myers Squibb

• KEYTRUDA: Merck

PD-1 and PD-L1 Inhibitors Pipeline Therapeutics Assessment

• PD-1 and PD-L1 Inhibitors Assessment by Product Type

• PD-1 and PD-L1 Inhibitors By Stage and Product Type

• PD-1 and PD-L1 Inhibitors Assessment by Route of Administration

• PD-1 and PD-L1 Inhibitors By Stage and Route of Administration

• PD-1 and PD-L1 Inhibitors Assessment by Molecule Type

• PD-1 and PD-L1 Inhibitors by Stage and Molecule Type

DelveInsight’s PD-1 and PD-L1 Inhibitors Report covers around 200+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further PD-1 and PD-L1 Inhibitors product details are provided in the report. Download the PD-1 and PD-L1 Inhibitors pipeline report to learn more about the emerging PD-1 and PD-L1 Inhibitors therapies

Some of the key companies in the PD-1 and PD-L1 Inhibitors Therapeutics Market include:

Key companies developing therapies for PD-1 and PD-L1 Inhibitors are – F. Hoffmann-La Roche AG, Sanofi S.A., Amgen Inc., AstraZeneca PLC, Pfizer Inc., Bristol-Myers Squibb Company, Others.

PD-1 and PD-L1 Inhibitors Pipeline Analysis:

The PD-1 and PD-L1 Inhibitors pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of PD-1 and PD-L1 Inhibitors with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for PD-1 and PD-L1 Inhibitors Treatment.

• PD-1 and PD-L1 Inhibitors key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• PD-1 and PD-L1 Inhibitors Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the PD-1 and PD-L1 Inhibitors market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about PD-1 and PD-L1 Inhibitors drugs and therapies

PD-1 and PD-L1 Inhibitors Pipeline Market Drivers

• Rise in prevalence of Cancer, PD-1 and PD-L1 Inhibitors are emerging as an important checkpoint inhibitors used as frontline treatment in various cancer are some of the important factors that are fueling the PD-1 and PD-L1 Inhibitors Market.

PD-1 and PD-L1 Inhibitors Pipeline Market Barriers

• However, high cost associated with the treatment, side effects associated with the treatment and other factors are creating obstacles in the PD-1 and PD-L1 Inhibitors Market growth.

Scope of PD-1 and PD-L1 Inhibitors Pipeline Drug Insight

• Coverage: Global

• Key PD-1 and PD-L1 Inhibitors Companies: Compass Therapeutics, Aurigene Discovery Technologies, RemeGen, Aurigene Discovery Technologies, Inhibrx, Effector Therapeutics, CytomX Therapeutics, Innovent Biologics, GlaxoSmithKline, Biocad, Genentech, Bristol Myers Squibb, Merck, and others

• Key PD-1 and PD-L1 Inhibitors Therapies: CTX-8371, CA 327, RC-98, AUR-106, INBRX 105, Tomivosertib, CX-072, IBI 323, Jemperli, BCD-100, TECENTRIQ, Opdivo, KEYTRUDA, and others

• PD-1 and PD-L1 Inhibitors Therapeutic Assessment: PD-1 and PD-L1 Inhibitors current marketed and PD-1 and PD-L1 Inhibitors emerging therapies

• PD-1 and PD-L1 Inhibitors Market Dynamics: PD-1 and PD-L1 Inhibitors market drivers and PD-1 and PD-L1 Inhibitors market barriers

Request for Sample PDF Report for PD-1 and PD-L1 Inhibitors Competitive Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: PD-1 and PD-L1 Inhibitors Competitor Landscape Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Compass Therapeutics, Aurigene Discovery Tech

DelveInsight’s “Parkinson’s Disease Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Parkinson’s Disease, historical and forecasted epidemiology as well as the Parkinson’s Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Parkinson’s Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Parkinson’s Disease Market Forecast

Some of the key facts of the Parkinson’s Disease Market Report:

• The Parkinson’s Disease market size was valued approximately USD 3,218 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034).

• In April 2025, US-based biotech company Cerevance is proceeding with its ongoing pivotal trial of solengepras for Parkinson’s disease, despite the candidate not demonstrating a clear advantage over placebo in a Phase II study. At the AD/PD 2025 conference in Vienna, the company shared results from the Phase II ASCEND trial (NCT06006247), which indicated that solengepras led to a non-statistically significant improvement in motor symptoms from baseline to week 12, as measured by the MDS-UPDRS Parts II+III.

• In February 2025, AstraZeneca’s diabetes medication Bydureon (exenatide) did not demonstrate effectiveness in slowing the progression of motor symptoms in Parkinson’s disease during a Phase III clinical trial. Led by University College London (UCL), the Exenatide-PD3 trial (NCT04232969) aimed to evaluate the impact of the GLP-1 receptor agonist on disease progression. However, findings published in The Lancet confirmed that the study failed to achieve both its primary and secondary endpoints. The trial involved two groups, with one receiving a weekly 2mg dose of Bydureon and the other a placebo.

• In January 2025, BlueRock Therapeutics, a US-based subsidiary of Bayer, is advancing its investigational cell therapy candidate, bemdaneprocel, for Parkinson’s disease into Phase III trials. This decision follows promising Phase I results showing the treatment was well tolerated. After receiving Regenerative Medicine Advanced Therapy (RMAT) designation and engaging in discussions with the US FDA, the Massachusetts-based company intends to initiate its registrational trial, exPDite-2, in the first half of 2025.

• In December 2024, Roche (SIX: RO, ROG; OTCQX: RHHBY) has released findings from the Phase IIb PADOVA trial evaluating prasinezumab in 586 individuals with early-stage Parkinson’s disease, all receiving stable symptomatic treatment for at least 18 months. While prasinezumab demonstrated potential clinical benefit in delaying confirmed motor progression (HR=0.84 [0.69–1.01], p=0.0657), it did not reach statistical significance. However, a pre-specified subgroup analysis revealed a stronger effect among participants treated with levodopa (75% of the cohort), with HR=0.79 [0.63–0.99]. The study also showed consistent positive trends across various secondary and exploratory endpoints. Prasinezumab maintained a favorable safety profile with no new safety concerns reported.

• In November 2024, Sunbird Bio unveiled new data demonstrating that its diagnostic technology accurately classified blood samples from Parkinson’s disease patients with 86% accuracy by directly detecting aggregated alpha-synuclein proteins.

• In September 2024, AbbVie’s newly acquired Parkinson’s disease candidate, tavapadon, notably alleviated disease symptoms in a Phase III trial. The Phase III TEMPO-1 trial (NCT04201093) assessed two daily doses of tavapadon (5mg and 15mg). The trial achieved its primary endpoint, with both dosage groups showing significant improvement in disease burden at week 26, as measured by the combined score from the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS).

• In August 2024, Gain Therapeutics has reported positive topline results from the Phase I clinical trial of GT-02287, a drug candidate for Parkinson’s disease. The trial evaluated the safety, tolerability, and pharmacokinetics of GT-02287 as a potential treatment for Parkinson’s.

• In July 2024, The U.S. Food and Drug Administration (FDA) approved Kisunla™ (donanemab-azbt, 350 mg/20 mL), a once-monthly injection for intravenous infusion by Eli Lilly and Company (NYSE: LLY). This treatment is aimed at adults with early symptomatic Alzheimer’s disease (AD), including those with mild cognitive impairment (MCI) and mild dementia, who have confirmed amyloid pathology. Kisunla is the first and only therapy targeting amyloid plaques with evidence supporting the discontinuation of treatment once these plaques are removed, potentially leading to reduced treatment costs and fewer infusions.

• The Parkinson’s disease market in the US was valued at around USD 1,883 million in 2023 and is expected to grow due to rising awareness of the disease and the introduction of new therapies.

• The combined market size of EU4 and the UK was approximately USD 988 million in 2023, accounting for nearly 31% of the total market revenue for the 7MM.

• Based on DelveInsight’s estimates, Germany held the largest market share among EU4 and the UK, with approximately USD 390 million in 2023. It was followed by France with around USD 218 million, and the UK with USD 130 million in the same year. These figures are expected to grow during the forecast period (2024–2034).

• In 2023, the Parkinson’s disease market in Japan was valued at around USD 348 million, and it is expected to grow during the forecast period.

• According to the analysis, the largest share of the market in 2023 was held by other and combination therapies, generating approximately USD 2,210 million in revenue.

• In 2023, the total number of diagnosed Parkinson’s disease cases in the US was approximately 1,210 thousand, and this figure is expected to rise during the forecast period (2024–2034) due to factors such as growing awareness, an aging population, and advancements in diagnostic procedures.

• In 2023, Japan had around 258 thousand diagnosed prevalent cases of Parkinson’s disease among the 7MM.

• In 2023, Germany had the highest number of diagnosed prevalent cases of Parkinson’s disease among the EU4 and the UK, with nearly 495 thousand cases, followed by France with approximately 277 thousand cases. Spain had the fewest, with around 149 thousand cases.

• In 2023, Japan recorded approximately 135 thousand male cases and 123 thousand female cases of diagnosed prevalent Parkinson’s disease. These numbers are expected to rise during the forecast period.

• In 2023, the US saw approximately 19 thousand Parkinson’s disease cases in the age group of ≤49 years, 215 thousand cases in the 50–64 years group, 449 thousand cases in the 65–74 years group, and 527 thousand cases in those aged ≥75 years.

• Key Parkinson’s Disease Companies: Amneal Pharmaceuticals, AbbVie, Newron Pharmaceuticals, Zambon, Eisai, Kyowa Kirin, Supernus Pharmaceutical/Britannia Pharmaceuticals, AbbVie, Mitsubishi Tanabe Pharma (NeuroDerm), Cerevance, Amneal Pharmaceutical, Pharma Two B, Jazz Pharmaceuticals, Chase Therapeutics Corporation, Mthera Pharma Co., Ltd., Bial R&D Investments, S.A., Hoffmann-La Roche, NeuroDerm Ltd., Tasly Pharmaceutical, BrainX Corporation, UCB Biopharma SRL, National Neuroscience Institute, GE Healthcare, Cerevel Therapeutics, LLC, Inhibikase Therapeutics, Inc., Bial – Portela C S.A., Neuraly, Inc., Forest Hills Lab, Intra-Cellular Therapies, Inc., FAScinate Therapeutics Inc., AC Immune SA, and others

• Key Parkinson’s Disease Therapies: CREXONT (carbidopa and levodopa) ER capsules, PRODUODOPA (foslevodopa/foscarbidopa), XADAGO/EQUFINA (safinamide), NOURIANZ/NOURIAST (istradefylline), SPN-830 (apomorphine infusion device), ABBV-951, ND0612, CVN-424, IPX203, P2B001, Suvecaltamide (JZP385), CTC-413, MT101-5, BIA 28-6156, RO7046015, ND0612, pimavanserin tartrate, Ceftriaxone, UCB0599, Tocovid Suprabio (HOV-12020), Altropane (123I) Injection, Tavapadon, IkT-148009, Opicapone, NLY01, Gemfibrozil, Lenrispodun, KM-819, ACI-7104.056, and others

• The Parkinson’s Disease epidemiology based on gender analyzed that there is male preponderance in the Parkinson’s disease cases in the 7MM

• The Parkinson’s Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Parkinson’s Disease pipeline products will significantly revolutionize the Parkinson’s Disease market dynamics.

Parkinson’s Disease Overview

Parkinson’s disease is a progressive neurodegenerative disorder that affects movement control. It is characterized by symptoms such as tremors, stiffness, slowness of movement, and balance difficulties. The disease occurs when nerve cells in the brain, particularly those producing dopamine, are damaged or die. The exact cause is unknown, but genetic and environmental factors may contribute.

Get a Free sample for the Parkinson’s Disease Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/parkinsons-disease-market-size-analysis-treatment

Parkinson’s Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Parkinson’s Disease Epidemiology Segmentation:

The Parkinson’s Disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Parkinson’s Disease

• Prevalent Cases of Parkinson’s Disease by severity

• Gender-specific Prevalence of Parkinson’s Disease

• Diagnosed Cases of Episodic and Chronic Parkinson’s Disease

Download the report to understand which factors are driving Parkinson’s Disease epidemiology trends @ Parkinson’s Disease Epidemiology Forecast

Parkinson’s Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Parkinson’s Disease market or expected to get launched during the study period. The analysis covers Parkinson’s Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Parkinson’s Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Parkinson’s Disease Therapies and Key Companies

• CREXONT (carbidopa and levodopa) ER capsules: Amneal Pharmaceuticals

• PRODUODOPA (foslevodopa/foscarbidopa): AbbVie

• XADAGO/EQUFINA (safinamide): Newron Pharmaceuticals/Zambon/Supernus Pharmaceuticals/Eisai

• NOURIANZ/NOURIAST (istradefylline): Kyowa Kirin

• SPN-830 (apomorphine infusion device): Supernus Pharmaceutical/Britannia Pharmaceuticals

• ABBV-951: AbbVie

• ND0612: Mitsubishi Tanabe Pharma(NeuroDerm)

• CVN-424: Cerevance

• IPX203: Amneal Pharmaceutical

• P2B001: Pharma Two B

• Suvecaltamide (JZP385): Jazz Pharmaceuticals

• CTC-413: Chase Therapeutics Corporation

• MT101-5: Mthera Pharma Co., Ltd.

• BIA 28-6156: Bial R&D Investments, S.A.

• RO7046015: Hoffmann-La Roche

• ND0612: NeuroDerm Ltd.

• pimavanserin tartrate: Tasly Pharmaceutical

• Ceftriaxone: BrainX Corporation

• UCB0599: UCB Biopharma SRL

• Tocovid Suprabio (HOV-12020): National Neuroscience Institute

• Altropane (123I) Injection: GE Healthcare

• Tavapadon: Cerevel Therapeutics, LLC

• IkT-148009: Inhibikase Therapeutics, Inc.

• Opicapone: Bial – Portela C S.A.

• NLY01: Neuraly, Inc.

• Gemfibrozil: Forest Hills Lab

• Lenrispodun: Intra-Cellular Therapies, Inc.

• KM-819: FAScinate Therapeutics Inc.

• ACI-7104.056: AC Immune SA

Discover more about therapies set to grab major Parkinson’s Disease market share @ Parkinson’s Disease Treatment Landscape

Parkinson’s Disease Market Drivers

• Growing research and development are increasing the demand for better diagnosis and treatment options for Parkinson’s Disease.

• In recent years, drugs with a novel mechanism of action and combinations are being investigated to overcome the challenges of this entity

Parkinson’s Disease Market Barriers

• The development of a disease-modifying drug can potentially increase the Parkinson’s Disease market share potential.

• In advanced countries, there is a huge annual psychological, social, and economic burden (QALY) due to Parkinson’s Disease.

Scope of the Parkinson’s Disease Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Parkinson’s Disease Companies: Amneal Pharmaceuticals, AbbVie, Newron Pharmaceuticals, Zambon, Eisai, Kyowa Kirin, Supernus Pharmaceutical/Britannia Pharmaceuticals, AbbVie, Mitsubishi Tanabe Pharma (NeuroDerm), Cerevance, Amneal Pharmaceutical, Pharma Two B, Jazz Pharmaceuticals, Chase Therapeutics Corporation, Mthera Pharma Co., Ltd., Bial R&D Investments, S.A., Hoffmann-La Roche, NeuroDerm Ltd., Tasly Pharmaceutical, BrainX Corporation, UCB Biopharma SRL, National Neuroscience Institute, GE Healthcare, Cerevel Therapeutics, LLC, Inhibikase Therapeutics, Inc., Bial – Portela C S.A., Neuraly, Inc., Forest Hills Lab, Intra-Cellular Therapies, Inc., FAScinate Therapeutics Inc., AC Immune SA, and others

• Key Parkinson’s Disease Therapies: CREXONT (carbidopa and levodopa) ER capsules, PRODUODOPA (foslevodopa/foscarbidopa), XADAGO/EQUFINA (safinamide), NOURIANZ/NOURIAST (istradefylline), SPN-830 (apomorphine infusion device), ABBV-951, ND0612, CVN-424, IPX203, P2B001, Suvecaltamide (JZP385), CTC-413, MT101-5, BIA 28-6156, RO7046015, ND0612, pimavanserin tartrate, Ceftriaxone, UCB0599, Tocovid Suprabio (HOV-12020), Altropane (123I) Injection, Tavapadon, IkT-148009, Opicapone, NLY01, Gemfibrozil, Lenrispodun, KM-819, ACI-7104.056, and others

• Parkinson’s Disease Therapeutic Assessment: Parkinson’s Disease current marketed and Parkinson’s Disease emerging therapies

• Parkinson’s Disease Market Dynamics: Parkinson’s Disease market drivers and Parkinson’s Disease market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Parkinson’s Disease Unmet Needs, KOL’s views, Analyst’s views, Parkinson’s Disease Market Access and Reimbursement

To know more about Parkinson’s Disease companies working in the treatment market, visit @ Parkinson’s Disease Clinical Trials and Therapeutic Assessment

Table of Contents

1. Parkinson’s Disease Market Report Introduction

2. Executive Summary for Parkinson’s Disease

3. SWOT analysis of Parkinson’s Disease

4. Parkinson’s Disease Patient Share (%) Overview at a Glance

5. Parkinson’s Disease Market Overview at a Glance

6. Parkinson’s Disease Disease Background and Overview

7. Parkinson’s Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Parkinson’s Disease

9. Parkinson’s Disease Current Treatment and Medical Practices

10. Parkinson’s Disease Unmet Needs

11. Parkinson’s Disease Emerging Therapies

12. Parkinson’s Disease Market Outlook

13. Country-Wise Parkinson’s Disease Market Analysis (2020–2034)

14. Parkinson’s Disease Market Access and Reimbursement of Therapies

15. Parkinson’s Disease Market Drivers

16. Parkinson’s Disease Market Barriers

17. Parkinson’s Disease Appendix

18. Parkinson’s Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Guarav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Parkinson’s Disease Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | AbbVie, Mitsubishi Tanabe Pharma (NeuroDerm), Cerevance, Amneal Pharma, Pharma Two B, Jazz Pharma

The Gingivitis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Gingivitis pipeline products will significantly revolutionize the Gingivitis market dynamics.

DelveInsight’s “Gingivitis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of Gingivitis, historical and forecasted epidemiology as well as Gingivitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Gingivitis market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Gingivitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Gingivitis Market Forecast

Some of the key facts of the Gingivitis Market Report:

• The Gingivitis Market Size is anticipated to grow with a significant CAGR during the study period (2019-2032).

• In April 2025, Scientists at Penn Dental Medicine have created a plant-derived therapy aimed at treating periodontal conditions like gingivitis and periodontitis. This anti-senescence approach, known as “senotherapy,” combines dasatinib, an enzyme inhibitor, with quercetin, a naturally occurring flavonoid compound found in plants.

• Globally the prevalence of Gingivitis is common in both developed and developing countries, around 20-50% of the population is affected by Gingivitis

• Prevalence of Gingivitis is common among people of age 18-40 years

• Over 50% of the adults suffer from Gingivitis on an average of 3 to 4 teeth

• The estimated prevalence of Gingivitis in children from age 12-to 15 years was about 29.6%

• Key Gingivitis Companies: Procter and Gamble, Colgate Palmolive, GlaxoSmithKline, Amyndas Pharmaceuticals, Biomedical Development Corporation, Rowpar Pharmaceuticals, and others

• Key Gingivitis Therapies: Stannous Fluoride Dentifrice, Amine, Stannous fluoride, AMY-101, Iocide Oral Rinse, ClōSYS®, and others

• The Gingivitis epidemiology based on gender analyzed that males and females both are equally more affected in the case of Gingivitis

Gingivitis Overview:

Gingivitis is a mild and early stage of gum disease caused by plaque buildup on the teeth. It leads to red, swollen, and bleeding gums, especially during brushing or flossing. Although not usually painful, if left untreated, gingivitis can progress to more severe gum conditions like periodontitis.

Get a Free sample for the Gingivitis Market Report:

https://www.delveinsight.com/report-store/gingivitis-market

Gingivitis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Gingivitis Epidemiology Segmentation:

The Gingivitis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Gingivitis

• Prevalent Cases of Gingivitis by severity

• Gender-specific Prevalence of Gingivitis

• Diagnosed Cases of Episodic and Chronic Gingivitis

Download the report to understand which factors are driving Gingivitis epidemiology trends @ Gingivitis Epidemiological Insights

Gingivitis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Gingivitis market or expected to get launched during the study period. The analysis covers Gingivitis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Gingivitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Gingivitis Therapies and Key Companies

• Stannous Fluoride Dentifrice: Procter and Gamble

• Amine: Colgate Palmolive

• Stannous fluoride: GlaxoSmithKline

• AMY-101: Amyndas Pharmaceuticals

• Iocide Oral Rinse: Biomedical Development Corporation

• ClōSYS®: Rowpar Pharmaceuticals

To know more about Gingivitis treatment, visit @ Gingivitis Medications

Gingivitis Market Drivers

• Rising prevalence of gingivitis

• Growing oral health awareness

• Expansion of OTC and irrigation devices

• Technological innovation

Gingivitis Market Barriers

• Limited awareness in developing regions

• High cost of advanced therapies

• Competition with general oral care products

• Access and infrastructure issues

Scope of the Gingivitis Market Report

• Study Period: 2019–2032

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Gingivitis Companies: Procter and Gamble, Colgate Palmolive, GlaxoSmithKline, Amyndas Pharmaceuticals, Biomedical Development Corporation, Rowpar Pharmaceuticals, and others

• Key Gingivitis Therapies: Stannous Fluoride Dentifrice, Amine, Stannous fluoride, AMY-101, Iocide Oral Rinse, ClōSYS®, and others

• Gingivitis Therapeutic Assessment: Gingivitis current marketed and Gingivitis emerging therapies

• Gingivitis Market Dynamics: Gingivitis market drivers and Gingivitis market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Gingivitis Unmet Needs, KOL’s views, Analyst’s views, Gingivitis Market Access and Reimbursement

Discover more about therapies set to grab major Gingivitis market share @ Gingivitis Treatment Landscape

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Gingivitis Patient Share (%) Overview at a Glance

5. Gingivitis Market Overview at a Glance

6. Gingivitis Disease Background and Overview

7. Gingivitis Epidemiology and Patient Population

8. Country-Specific Patient Population of Gingivitis

9. Gingivitis Current Treatment and Medical Practices

10. Unmet Needs

11. Gingivitis Emerging Therapies

12. Gingivitis Market Outlook

13. Country-Wise Gingivitis Market Analysis (2018–2030)

14. Market Access and Reimbursement of Therapies

15. Gingivitis Market drivers

16. Gingivitis Market barriers

17. Appendix

18. Gingivitis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Gingivitis Market Set to Grow Substantially Through 2032, DelveInsight Projects | Procter and Gamble, Colgate Palmolive, GlaxoSmithKline, Amyndas Pharma, Rowpar Pharma